Kazakhstan cancer drug DVC advances to second clinical trial phase in Astana
This digest was compiled by AI from multiple sources — links to the originals are below.
Kazakhstan's experimental cancer drug DVC is in the second phase of clinical trials at an oncology center in Astana, Science and Higher Education Minister Sayasat Nurbek said at a government briefing. Researchers are determining how patients respond to different doses, and the ministry aims to complete this phase by the end of 2026 before applying for drug registration.
Key Facts
- DVC is being developed by the National Laboratory Astana at Nazarbayev University and is in second-phase clinical trials at an oncology center in Astana.
- Science and Higher Education Minister Sayasat Nurbek said researchers are determining how patients react to larger and smaller doses.
- Nurbek said the ministry will try to complete the second phase by the end of 2026 and submit DVC for preliminary registration.
- In May, Nurbek said all participants in the first trial phase remained alive and some patients showed tumor reduction.
- Kazakhstan first seeks registration in Kazakhstan and the Eurasian Economic Union; US, European, and Asian markets would require separate regulatory approvals.
Phase II Trial Progress
DVC is being developed by the National Laboratory Astana at Nazarbayev University and is in second-phase clinical trials at an oncology center in Astana, Science Minister Sayasat Nurbek told a government briefing. Researchers are testing how patients' bodies respond to larger and smaller doses to identify the safest and most effective dosage. Nurbek said the ministry will try to finish this phase by the end of 2026 and submit DVC for preliminary registration. The National Center under the Health Ministry is assisting and awaits confirmed results from the second phase before registration checks begin. DVC remains an experimental drug and is not yet a registered medicine with fully proven safety and efficacy.
Registration Path
Once the second-phase results are confirmed, the developers plan to apply to Kazakhstan's National Center for Registration of Medicines. The first goal is official approval in Kazakhstan and the Eurasian Economic Union. Entering US, European, or Asian markets would require separate checks by local regulators, with US regulatory approval seen as among the strictest. Nurbek said the ministry's task is for DVC to work as an official drug within the Eurasian Economic Union.
2 sources
Kazakhstan cancer drug DVC advances to second clinical trial phase in Astana
